Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS) in a report released on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cellectis Stock Performance

CLLS opened at $2.99 on Friday. The company has a market cap of $166.18 million, a P/E ratio of -1.74 and a beta of 3.08. Cellectis has a one year low of $0.96 and a one year high of $3.77. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.20 and a current ratio of 2.20. The business’s 50-day simple moving average is $2.60 and its 200-day simple moving average is $2.69.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter. The company had revenue of $1.99 million during the quarter. Cellectis had a negative net margin of 346.65% and a negative return on equity of 73.03%. As a group, equities research analysts expect that Cellectis will post -1.06 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Baillie Gifford & Co. increased its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 1.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 827,248 shares of the biotechnology company’s stock after buying an additional 10,605 shares during the quarter. Baillie Gifford & Co. owned about 1.49% of Cellectis worth $2,192,000 as of its most recent SEC filing. Institutional investors and hedge funds own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.